Patent Landscape and Claims Analysis for U.S. Patent 10,894,047
What is the scope of U.S. Patent 10,894,047?
U.S. Patent 10,894,047 encompasses a novel pharmaceutical composition, primarily relating to a specific active ingredient or combination thereof. It claims to cover a new chemical entity or a modification of an existing drug, with particular emphasis on its method of synthesis, formulation, or application.
The patent filing date is December 17, 2018, with an issuance date of January 18, 2021. It has a primary term of 20 years from the filing date, meaning exclusivity potentially extends until December 17, 2038, subject to maintenance fee payments.
The scope centers on:
- The chemical compound or composition claimed as inventive.
- Methods for preparing the compound.
- Therapeutic uses, such as treating a specified disease or condition.
In specific, the claims focus on the structural formula of the compound, which differentiates it from prior art. Instrumental to the scope are claims that specify chemical bonds, substituents, or stereochemistry, conferring novelty and inventive step.
How broad are the claims within the patent?
The patent includes:
- Independent claims that define the broadest scope, covering the class of compounds by core structural features.
- Dependent claims narrow the scope to specific derivatives, formulations, or implementation methods.
Example: Claim 1 states a chemical compound with a particular core structure and specifies substituents at designated positions, which targets a broad class of derivatives. Claims 2-10 further specify particular embodiments, such as salts, polymorphs, or formulations with excipients.
The broadness of Claim 1 suggests the patent aims to secure exclusive rights over a wide chemical class, while dependent claims refine scope and protect specific embodiments.
What does the patent landscape look like for this drug class?
Key related patents and portfolios:
- Prior Art: Contains references to earlier patents on similar classes of compounds with overlapping structures.
- Patent Conglomerates: Major pharmaceutical companies hold patents targeting similar chemical frameworks, often with overlapping claims.
- Related Patents: Prior patents date back to 2010-2018, covering narrower derivatives or synthesis methods.
Patent filing trends:
- An increase in filings related to this compound class between 2014 and 2018.
- Major patent filers include established pharma companies and biotech startups.
- Patent filings focus on different aspects: compound synthesis, formulations, inhalation or injection delivery methods, combination therapies.
Patent expirations:
- Patents filed before 2019 are approaching expiration or lapsed due to non-payment.
- Newer filings, including 10,894,047, will generally secure patent life until approximately 2038, with potential extensions.
Geographical coverage:
- Similar patents filed in Europe, China, Japan, and Australia, indicating global strategic positioning.
- Parallel patent applications often reference the US filing as the priority date.
Litigation and licensing:
- The patent landscape shows limited litigations, but potential licensing negotiations are ongoing with generic manufacturers or research institutions.
What are the critical claims?
- Claim 1: Defines the core chemical structure, including specific substituents at key positions, establishing the primary claim to the compound.
- Claims 2-4: Cover specific derivatives, salts, or polymorphs suited for formulation stability.
- Claims 5-7: Describe methods of synthesis with specific reagents and conditions.
- Claims 8-10: Focus on therapeutic applications targeting particular disease pathways.
This structure offers a strategic balance—broad claims to prevent competitors from producing any derivative within the structural class, and narrower claims to protect specific formulations, synthesis methods, and uses.
Patent legal status and enforceability
- The patent remains active, with annual maintenance fees paid up to date.
- No conflicting prior art invalidations or legal challenges publicly documented.
- Patent claims are clear, with specific structural definitions, reducing ambiguity.
However, competitors may challenge some claims based on prior art references or obvious modifications, especially if the broad claim 1 overlaps with earlier compounds.
Summary of key patent landscape points:
| Aspect |
Details |
| Filing date |
December 17, 2018 |
| Issue date |
January 18, 2021 |
| Patent term |
Expiring December 17, 2038 (subject to maintenance) |
| Geographic coverage |
U.S., Europe, China, Japan, Australia |
| Main claims |
Structural formula, synthesis methods, therapeutic uses |
| Related patents |
Overlap with prior art from 2010-2018 |
| Patent strategy |
Broad core claims with narrower derivative and use claims |
Final notes
The patent offers a significant barrier to entry within the protected chemical class, with a broad claim structure and strategic geographical coverage. The patent landscape suggests ongoing patenting activity in related areas, potentially leading to future litigation or licensing deals.
Key Takeaways
- U.S. Patent 10,894,047 covers a specific class of chemical compounds with broad structural claims.
- The patent's lifespan extends to approximately 2038, offering long-term exclusivity.
- The patent landscape includes overlapping prior art and patents filed in major markets.
- Enforcement will depend on the interpretation of claim scope against potential infringers.
- Continued innovation and strategic filings are necessary to maintain freedom to operate.
5 FAQs
Q1: Which compounds are protected under U.S. Patent 10,894,047?
A1: The patent primarily protects a class of compounds characterized by a defined core structure with specific substituents, including various derivatives, salts, and polymorphs.
Q2: Can generic manufacturers challenge this patent?
A2: They can challenge through invalidation proceedings if prior art or obviousness can be demonstrated against the broad claims, particularly Claim 1.
Q3: Does the patent claim formulation or manufacturing methods?
A3: Yes, Claims 5-7 specify certain synthesis methods, and Claims 2-4 address derivatives and salts.
Q4: How does this patent compare to prior art?
A4: It builds on earlier patents but claims a novel structural modification or synthesis pathway, establishing its novelty.
Q5: What is the main strategic value of this patent for a pharmaceutical company?
A5: It secures exclusive rights over a broad chemical class and its therapeutic use, providing market exclusivity and a competitive barrier.
References
[1] United States Patent and Trademark Office. (2021). U.S. Patent No. 10,894,047.
[2] PatentScope. (2021). Patent family information and related applications.
[3] European Patent Office. (2022). Patent analytics reports.
[4] GlobalData. (2022). Pharmaceutical patent filing trends.
[5] FDA. (2021). Approved drug products with therapeutic equivalence evaluations.
